Profound Medical to Participate in A.G.P.’s Virtual Healthcare Conference
TORONTO, May 18, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device...
Day: May 18, 2023
HTG to Highlight the Advantages of its Drug Discovery Engine at the 2023 BIO International Convention
TUCSON, Ariz., May 18, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools...
iCAD’s ProFound AI Breast Suite Wins U.S. General Services Administration’s AI Healthcare Challenge Award
Company presented portfolio of breast cancer detection, density assessment and risk evaluation solutions at the competition, focused on improving health...
Smart for Life Announces $1.58 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
MIAMI, May 18, 2023 (GLOBE NEWSWIRE) -- Smart for Life, Inc. (Nasdaq: SMFL) (“Smart for Life” or the “Company”), a...
Galera Announces FDA Orphan Drug Designation Granted to Rucosopasem for Pancreatic Cancer
Rucosopasem in clinical development to augment the anti-cancer efficacy of stereotactic body radiation therapyMALVERN, Pa., May 18, 2023 (GLOBE NEWSWIRE)...
Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer
Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer Arun Balakumaran M.D., Ph.D, appointed Chief Medical Officer of Replay...
Replimune Reports Fiscal Fourth Quarter and Year Ended 2023 Financial Results and Provides Corporate Update
Topline data disclosure from the registration-directed CERPASS clinical trial of RP1 combined with Libtayo® (cemiplimab-rwlc) in cutaneous squamous cell carcinoma...
Science 37 Wins 2023 MedTech Breakthrough Award for “Best Overall Clinical Trial Platform”
Science 37's unified platform that powers the Metasite receives award for outstanding digital health and technology innovationRESEARCH TRIANGLE PARK, N.C., May...
Cognition Therapeutics Publishes Clinical Evidence that CT1812 Displaces Aβ Oligomers from Binding to Neuronal Synapses in Alzheimer’s Disease
- First Human Evidence that CT1812 Selectively Engages Aβ OligomersPURCHASE, N.Y., May 18, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc....
Standard BioTools Announces NGS Library Preparation as an Upgrade on the X9 High-Throughput Genomics System
Supporting discovery through screening, the X9 is the only system integrating real-time PCR and NGS library preparationSOUTH SAN FRANCISCO, Calif.,...
FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia
Met primary endpoint of noninferiority of roxadustat to erythropoietin alfaPlan to file supplemental New Drug Application in ChinaSAN FRANCISCO and...
Orchard Therapeutics Presents Data from Research Programs at ASGCT Demonstrating the Ability of HSC Gene Therapy to Address Larger Indications
Preclinical proof-of-concept data show the therapeutic potential of OTL-104 for NOD2 Crohn’s disease, a severe and treatment-refractory form of the...
Kymera Therapeutics Presents Clinical Data from the Phase 1 Trial of IRAK4 Degrader, KT-474 (SAR444656), at the European Academy of Dermatology and Venereology Symposium
In the Phase 1 trial, KT-474 showed evidence of robust IRAK4 degradation in blood and skin lesions as well as...
Tonix Pharmaceuticals to Participate in the A.G.P. Virtual Healthcare Conference
CHATHAM, N.J., May 18, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today...
MedAvail to Report First Quarter 2023 Financial Results on May 18
Management to host investor conference call and webcast at 4:30pm EDT todayPHOENIX, May 18, 2023 (GLOBE NEWSWIRE) -- MedAvail Holdings,...
Breckenridge Distillery Announces Limited Edition Bourbon Collaboration With Flaviar For Father’s Day
Flaviar, America’s Largest Whiskey Club, Will Exclusively Launch Breckenridge Distillery’s Dad’s Stash Limited Reserve Blend Breckenridge Distillery’s Dad’s Stash Limited...
Alimera Acquires U.S. Commercial Rights to YUTIQ®
Expected to be immediately accretive to revenue and Adjusted EBITDA in 2023 Alimera projects at least $100 million of consolidated...
EyePoint Pharmaceuticals Announces Sale of YUTIQ® to Alimera Sciences, Inc. for $82.5 Million Cash Plus Royalties
–$75M paid at closing with an additional $7.5M payable in equal quarterly installments in 2024 – All outstanding bank debt...
PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne Muscular Dystrophy
- CONNECT1-EDO51 will assess dystrophin levels, exon skipping data and safety data following multiple doses of PGN-EDO51 in patients with...
ASLAN Pharmaceuticals Doses First Patient in Phase 2a Trial of Farudodstat in Alopecia Areata
The Phase 2a, proof-of-concept study, called FAST-AA (FArudodstat STudy in Alopecia Areata), will enroll approximately 60 adult patients in the...